A Phase 3 interventional study of CP 690,550 5 mg and CP 690,550 10 mg in Psoriasis, sponsored by Pfizer. Completed at 122 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 2nd largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 5th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,101 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2010, is one of 10 in phase 3, and was the 31st registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: CP 690,550 5 mg
Drug: CP 690,550 10 mg
Biological: Etanercept 50 mg
Other: Placebo
CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
Time frame: Week 12
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.
Time frame: Week 12
Percentage of Participants With a PGA Response of "Clear" or "Almost Clear" During the 12-Week Double-Blind Treatment
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).
Time frame: Weeks 2, 4, and 8
Percentage of Participants in Each PGA Category During the 12-Week Double-Blind Treatment
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
Time frame: Baseline and Weeks 2, 4, 8, and 12
Percentage of Participants With a PASI75 Response During the 12-Week Double-Blind Treatment
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.
Time frame: Weeks 2, 4, and 8
Mean PASI Score During the 12-Week Double-Blind Treatment
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Time frame: Baseline and Weeks 2, 4, 8, and 12
Mean Change From Baseline in PASI Score During the 12-Week Double-Blind Treatment
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Time frame: Weeks 2, 4, 8, and 12
Mean PASI Component Scores by Body Region During the 12-Week Double Blind Treatment
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Time frame: Baseline and Weeks 2, 4, 8, and 12
Mean Change From Baseline in PASI Component Scores by Body Region During the 12-Week Double Blind Treatment
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Time frame: Weeks 2, 4, 8, and 12
Mean Percentage of Total Psoriatic BSA During the 12-Week Double-Blind Treatment
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 2, 4, 8, and 12
Mean Percent Change From Baseline in Total Psoriatic BSA During the 12-Week Double-Blind Treatment
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Weeks 2, 4, 8, and 12
Percentage of Participants Who Achieved a 50% Reduction in PASI Relative to Baseline (PASI50) During the 12-Week Double-Blind Treatment
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.
Time frame: Weeks 2, 4, 8, and 12
Median Time to PASI50 Response During the 12-Week Double-Blind Treatment
Time frame: Baseline up to Week 12
Percentage of Participants Who Achieved a 90% Reduction in PASI Relative to Baseline (PASI90) During the 12-Week Double-Blind Treatment
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.
Time frame: Weeks 2, 4, 8, and 12
Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment
Time frame: Baseline up to Week 12
Percentage of Participants With a PASI Score Greater Than or Equal to (≥)125% of the Baseline PASI Score During the 12-Week Double-Blind Treatment
Time frame: Weeks 2, 4, 8, and 12
Mean Itch Severity Item (ISI) Score During the 12-Week Double-Blind Treatment
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline, Weeks 2, 4, 8, and 12
Mean Change From Baseline in ISI Score During the 12-Week Double-Blind Treatment
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 2, 4, 8, and 12
Percentage of Participants Achieving an ISI Score of 0 During the 12-Week Double-Blind Treatment
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 2, 4, 8, and 12
Mean Dermatology Life Quality Index (DLQI) Score During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline and Weeks 4 and 12
Mean Change From Baseline in DLQI Score During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4 and 12
Mean DLQI Subscale Scores During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Time frame: Baseline and Weeks 4 and 12
Mean Change From Baseline in DLQI Subscale Scores During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4 and 12
Percentage of Participants Achieving DLQI Response ≥5 During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Weeks 4 and 12
Percentage of Participants Achieving DLQI Response ≤1 During the 12-Week Double-Blind Treatment
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Weeks 4 and 12
Median Time to DLQI Response
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.
Time frame: Weeks 4 and 12
Mean Short Form 36 (SF-36) Mental Component Summary (MCS) and Physical Component Summary (PCS) Scores at Baseline and Week 12
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 12
Mean SF-36 Domain Scores at Baseline and Week 12
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 12
Mean Change From Baseline in SF-36 MCS and PCS Scores
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.
Time frame: Week 12
Mean Change From Baseline in SF-36 Domain Scores
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Time frame: Week 12
Percentage of Participants in Each Patient Global Assessment of Psoriasis (PtGA) Category During the 12-Week Double-Blind Treatment
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Time frame: Baseline and Weeks 2, 4, and 8
Percentage of Participants With a PtGA Response During the 12-Week Double-Blind Treatment
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.
Time frame: Weeks 2, 4, 8, and 12
Percentage of Participants in Each Patient Satisfaction With Study Medication (PSSM) Category During the 12-Week Double-Blind Treatment
The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.
Time frame: Week 12
Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12
The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.
Time frame: Week 12
Mean European Quality of Life 5 Dimension (EQ-5D) Health State Utility Score During the 12-Week Double-Blind Treatment
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline and Week 12
Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Week 12
Mean EQ-5D Visual Analog Score (VAS) During the 12-Week Double-Blind Treatment
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline and Week 12
Mean Change From Baseline in EQ-5D VAS at Week 12
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
Time frame: Week 12
Dimension Health State EQ-5D Score During the 12-Week Double-Blind Treatment
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
Time frame: Baseline and Week 12
Mean Change From Baseline in EQ-5D Dimension Health State Score at Week 12
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
Time frame: Week 12
Percentage of Participants Interacting With Healthcare Professionals During the 12-Week Double-Blind Treatment
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners \[GPs\], primary care physicians \[PCPs\], or family medicine physicians \[FMP\], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.
Time frame: Baseline (BL) and Week 12
Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment
Time frame: Week 12
Percentage of Participants Employed or Not Employed and the Impact of Psoriasis on Work
Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.
Time frame: Baseline and Week 12
Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment
Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.
Time frame: Week 12
Mean Psoriasis Quality of Life 12 (PQOL-12) Score During the 12-Week Double-Blind Treatment
The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.
Time frame: Baseline and Week 12
Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment
The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.
Time frame: Week 12
| Milestone | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Started | 329 | 330 | 335 | 107 |
| Completed | 306 | 306 | 313 | 95 |
| Not completed | 23 | 24 | 22 | 12 |
| Withdrew: Lack of efficacy | 5 | 2 | 2 | 3 |
| Withdrew: Protocol violation | 5 | 2 | 3 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 2 | 2 |
| Withdrew: Screen failure | 3 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 4 | 2 | 2 |
| Withdrew: Other | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event | 3 | 11 | 12 | 4 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Percentage of Participants With a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12 | 47.11 | 68.18 | 66.27 | 14.95 |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75 percent (%) reduction in PASI relative to baseline/Day 1.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 12 | 39.51 | 63.64 | 58.81 | 5.61 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response is defined as 0 (clear) or 1 (almost clear).
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=325,326,331,107) | 6.77 | 10.74 | 7.85 | 1.87 |
| Week 4 (n=320,323,328,102) | 21.25 | 35.91 | 28.35 | 3.92 |
| Week 8 (n=314,316,322,100) | 40.45 | 63.61 | 60.87 | 13.00 |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 to 4). The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline, Clear (n=329,330,335,107) | 0.0 | 0.0 | 0.0 | 0.0 |
| Baseline, Almost Clear (n=329,330,335,107) | 0.0 | 0.0 | 0.0 | 0.0 |
| Baseline, Mild (n=329,330,335,107) | 1.8 | 1.2 | 1.2 | 2.8 |
| Baseline, Moderate (n=329,330,335,107) | 80.2 | 83.3 | 80.9 | 82.2 |
| Baseline, Severe (n=329,330,335,107) | 17.9 | 15.5 | 17.9 | 15.0 |
| Week 2, Clear (n=325,326,331,107) | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 2, Almost Clear (n=325,326,331,107) | 6.8 | 10.7 | 7.9 | 1.9 |
| Week 2, Mild (n=325,326,331,107) | 38.5 | 47.9 | 42.6 | 25.2 |
| Week 2, Moderate (n=325,326,331,107) | 48.9 | 38.3 | 45.6 | 64.5 |
| Week 2, Severe (n=325,326,331,107) | 5.8 | 3.1 | 3.9 | 8.4 |
| Week 4, Clear (n=320,323,328,102) | 1.9 | 2.5 | 0.6 | 0.0 |
| Week 4, Almost Clear (n=320,323,328,102) | 19.4 | 33.4 | 27.7 | 3.9 |
| Week 4, Mild (n=320,323,328,102) | 46.3 | 44.3 | 51.5 | 34.3 |
| Week 4, Moderate (n=320,323,328,102) | 30.0 | 17.6 | 19.5 | 55.9 |
| Week 4, Severe (n=320,323,328,102) | 2.5 | 2.2 | 0.6 | 5.9 |
| Week 8, Clear (n=314,316,322,100) | 5.4 | 14.2 | 9.0 | 0.0 |
| Week 8, Almost Clear (n=314,316,322,100) | 35.0 | 49.4 | 51.9 | 13.0 |
| Week 8, Mild (n=314,316,322,100) | 41.4 | 25.0 | 30.1 | 35.0 |
| Week 8, Moderate (n=314,316,322,100) | 15.9 | 10.8 | 8.1 | 49.0 |
| Week 8, Severe (n=314,316,322,100) | 2.2 | 0.6 | 0.9 | 3.0 |
| Week 12, Clear (n=314,316,322,100) | 11.8 | 27.0 | 21.0 | 2.1 |
| Week 12, Almost Clear (n=313,311,309,95) | 37.7 | 45.3 | 50.8 | 14.7 |
| Week 12, Mild (n=313,311,309,95) | 33.5 | 19.3 | 21.4 | 36.8 |
| Week 12, Moderate (n=313,311,309,95) | 15.7 | 7.4 | 5.5 | 42.1 |
| Week 12, Severe (n=313,311,309,95) | 1.3 | 1.0 | 1.3 | 4.2 |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to baseline/Day 1.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,327,331,106) | 1.53 | 2.75 | 0.91 | 0.00 |
| Week 4 (n=319,323,328,102) | 10.34 | 19.81 | 8.23 | 0.00 |
| Week 8 (n=315,319,323,99) | 28.57 | 52.35 | 42.72 | 3.03 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=329,330,335,107) | 23.13 ± 0.48 | 23.29 ± 0.53 | 22.73 ± 0.53 | 22.78 ± 0.88 |
| Week 2 (n=326,327,328,102) | 18.16 ± 0.47 | 16.81 ± 0.53 | 17.29 ± 0.49 | 21.26 ± 0.95 |
| Week 4 (n=319,323,328,102) | 14.46 ± 0.46 | 12.13 ± 0.52 | 12.73 ± 0.44 | 20.06 ± 0.94 |
| Week 8 (n=315,319,323,99) | 10.63 ± 0.44 | 7.59 ± 0.48 | 7.70 ± 0.38 | 17.91 ± 0.99 |
| Week 12 (n=313,311,309,95) | 8.80 ± 0.43 | 5.77 ± 0.45 | 5.42 ± 0.36 | 17.39 ± 1.06 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,327,331,106) | -5.03 ± 0.31 | -6.47 ± 0.31 | -5.48 ± 0.29 | -1.58 ± 0.46 |
| Week 4 (n=319,323,328,102) | -8.83 ± 0.42 | -11.30 ± 0.43 | -10.14 ± 0.39 | -2.58 ± 0.62 |
| Week 8 (n=315,319,323,99) | -12.62 ± 0.52 | -15.81 ± 0.51 | -15.20 ± 0.51 | -4.82 ± 0.81 |
| Week 12 (n=313,311,309,95) | -14.55 ± 0.60 | -17.54 ± 0.54 | -17.55 ± 0.57 | -5.33 ± 0.97 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Head/Neck Erythema, Baseline (n=329,329,335,107) | 2.28 ± 0.05 | 2.36 ± 0.05 | 2.32 ± 0.05 | 2.40 ± 0.09 |
| Head/Neck Erythema, Week 2 (n=326,326,331,106) | 1.82 ± 0.05 | 1.65 ± 0.05 | 1.76 ± 0.06 | 2.27 ± 0.09 |
| Head/Neck Erythema, Week 4 (n=320,323,328,102) | 1.48 ± 0.05 | 1.18 ± 0.05 | 1.23 ± 0.05 | 2.03 ± 0.09 |
| Head/Neck Erythema, Week 8 (n=315,319,323,99) | 1.19 ± 0.06 | 0.78 ± 0.05 | 0.69 ± 0.05 | 1.89 ± 0.10 |
| Head/Neck Erythema, Week 12 (n=313,311,309,95) | 1.04 ± 0.06 | 0.65 ± 0.05 | 0.48 ± 0.04 | 1.74 ± 0.11 |
| Head/Neck Induration, Baseline (n=329,329,335,107) | 2.04 ± 0.05 | 2.08 ± 0.05 | 1.96 ± 0.06 | 2.12 ± 0.10 |
| Head/Neck Induration, Week 2 (n=326,326,331,106) | 1.60 ± 0.05 | 1.44 ± 0.05 | 1.46 ± 0.06 | 1.97 ± 0.10 |
| Head/Neck Induration, Week 4 (n=320,323,328,102) | 1.21 ± 0.05 | 0.94 ± 0.05 | 1.01 ± 0.05 | 1.69 ± 0.10 |
| Head/Neck Induration, Week 8 (n=315,319,323,99) | 0.96 ± 0.05 | 0.59 ± 0.05 | 0.54 ± 0.05 | 1.57 ± 0.10 |
| Head/Neck Induration, Week 12 (n=313,311,309,95) | 0.87 ± 0.05 | 0.49 ± 0.04 | 0.37 ± 0.04 | 1.41 ± 0.11 |
| Head/Neck Scaling, Baseline (n=329,329,335,107) | 2.29 ± 0.06 | 2.38 ± 0.06 | 2.28 ± 0.06 | 2.33 ± 0.10 |
| Head/Neck Scaling, Week 2 (n=326,326,331,106) | 1.75 ± 0.06 | 1.63 ± 0.06 | 1.60 ± 0.06 | 2.15 ± 0.10 |
| Head/Neck Scaling, Week 4 (n=320,323,328,102) | 1.38 ± 0.06 | 1.07 ± 0.06 | 1.16 ± 0.05 | 1.80 ± 0.11 |
| Head/Neck Scaling, Week 8 (n=315,319,323,99) | 1.12 ± 0.06 | 0.70 ± 0.05 | 0.65 ± 0.05 | 1.66 ± 0.11 |
| Head/Neck Scaling, Week 12 (n=313,311,309,95) | 0.98 ± 0.06 | 0.60 ± 0.05 | 0.46 ± 0.05 | 1.51 ± 0.11 |
| Upper Limbs Erythema, Baseline (n=329,329,335,107) | 2.87 ± 0.04 | 2.87 ± 0.04 | 2.88 ± 0.04 | 2.92 ± 0.07 |
| Upper Limbs Erythema, Week 2 (n=326,326,331,106) | 2.35 ± 0.04 | 2.18 ± 0.05 | 2.27 ± 0.05 | 2.75 ± 0.07 |
| Upper Limbs Erythema, Week 4 (n=320,323,328,102) | 1.92 ± 0.05 | 1.73 ± 0.05 | 1.77 ± 0.05 | 2.61 ± 0.07 |
| Upper Limbs Erythema, Week 8 (n=315,319,323,99) | 1.55 ± 0.05 | 1.27 ± 0.05 | 1.25 ± 0.05 | 2.42 ± 0.08 |
| Upper Limbs Erythema, Week 12 (n=313,311,309,95) | 1.45 ± 0.06 | 1.07 ± 0.05 | 0.94 ± 0.05 | 2.32 ± 0.08 |
| Upper Limbs Induration Baseline(n=329,329,335,107) | 2.69 ± 0.04 | 2.76 ± 0.04 | 2.72 ± 0.04 | 2.79 ± 0.07 |
| Upper Limbs Induration, Week 2 (n=326,326,331,106) | 2.17 ± 0.05 | 2.03 ± 0.05 | 2.13 ± 0.05 | 2.54 ± 0.07 |
| Upper Limbs Induration, Week 4 (n=320,323,328,102) | 1.76 ± 0.05 | 1.54 ± 0.05 | 1.59 ± 0.05 | 2.36 ± 0.08 |
| Upper Limbs Induration, Week 8 (n=315,319,323,99) | 1.43 ± 0.06 | 1.13 ± 0.05 | 1.18 ± 0.05 | 2.12 ± 0.09 |
| Upper Limbs Induration, Week 12 (n=313,311,309,95) | 1.31 ± 0.06 | 1.01 ± 0.05 | 0.81 ± 0.05 | 2.08 ± 0.09 |
| Upper Limbs Scaling, Baseline (n=329,329,335,107) | 2.66 ± 0.04 | 2.72 ± 0.04 | 2.73 ± 0.04 | 2.63 ± 0.08 |
| Upper Limbs Scaling, Week 2 (n=326,326,331,106) | 2.11 ± 0.05 | 2.00 ± 0.05 | 2.03 ± 0.05 | 2.35 ± 0.09 |
| Upper Limbs Scaling, Week 4 (n=320,323,328,102) | 1.71 ± 0.05 | 1.50 ± 0.05 | 1.54 ± 0.05 | 2.22 ± 0.10 |
| Upper Limbs Scaling, Week 8 (n=315,319,323,99) | 1.39 ± 0.06 | 1.11 ± 0.05 | 1.07 ± 0.05 | 1.98 ± 0.09 |
| Upper Limbs Scaling, Week 12 (n=313,311,309,95) | 1.30 ± 0.06 | 1.00 ± 0.05 | 0.82 ± 0.05 | 1.95 ± 0.10 |
| Trunk Erythema, Baseline (n=329,329,335,107) | 2.95 ± 0.04 | 2.88 ± 0.04 | 2.91 ± 0.04 | 2.97 ± 0.06 |
| Trunk Erythema, Week 2 (n=326,326,331,106) | 2.40 ± 0.05 | 2.20 ± 0.05 | 2.27 ± 0.05 | 2.75 ± 0.07 |
| Trunk Erythema, Week 4 (n=320,323,328,102) | 2.03 ± 0.05 | 1.75 ± 0.05 | 1.76 ± 0.05 | 2.59 ± 0.07 |
| Trunk Erythema, Week 8 (n=315,319,323,99) | 1.71 ± 0.06 | 1.23 ± 0.05 | 1.24 ± 0.05 | 2.41 ± 0.09 |
| Trunk Erythema, Week 12 (n=313,311,309,95) | 1.53 ± 0.06 | 0.97 ± 0.06 | 0.89 ± 0.05 | 2.33 ± 0.10 |
| Trunk Induration, Baseline (n=329,329,335,107) | 2.75 ± 0.04 | 2.70 ± 0.05 | 2.66 ± 0.05 | 2.66 ± 0.07 |
| Trunk Induration, Week 2 (n=326,326,331,106) | 2.26 ± 0.05 | 2.01 ± 0.05 | 2.05 ± 0.05 | 2.40 ± 0.07 |
| Trunk Induration, Week 4 (n=320,323,328,102) | 1.83 ± 0.05 | 1.50 ± 0.05 | 1.50 ± 0.05 | 2.26 ± 0.07 |
| Trunk Induration, Week 8 (n=315,319,323,99) | 1.50 ± 0.06 | 0.97 ± 0.05 | 0.98 ± 0.05 | 2.06 ± 0.09 |
| Trunk Induration, Week 12 (n=313,311,309,95) | 1.33 ± 0.06 | 0.80 ± 0.05 | 0.66 ± 0.05 | 2.03 ± 0.09 |
| Trunk Scaling, Baseline (n=329,329,335,107) | 2.64 ± 0.04 | 2.66 ± 0.05 | 2.57 ± 0.05 | 2.61 ± 0.07 |
| Trunk Scaling, Week 2 (n=326,326,331,106) | 2.12 ± 0.05 | 1.92 ± 0.06 | 1.93 ± 0.05 | 2.36 ± 0.09 |
| Trunk Scaling, Week 4 (n=320,323,328,102) | 1.73 ± 0.05 | 1.39 ± 0.05 | 1.44 ± 0.05 | 2.12 ± 0.09 |
| Trunk Scaling, Week 8 (n=315,319,323,99) | 1.47 ± 0.06 | 0.94 ± 0.05 | 0.90 ± 0.05 | 1.86 ± 0.08 |
| Trunk Scaling, Week 12 (n=313,311,309,95) | 1.28 ± 0.06 | 0.74 ± 0.05 | 0.62 ± 0.05 | 1.91 ± 0.10 |
| Lower Limbs Erythema, Baseline (n=329,329,335,107) | 3.12 ± 0.03 | 3.13 ± 0.04 | 3.14 ± 0.03 | 3.10 ± 0.06 |
| Lower Limbs Erythema, Week 2 (n=326,326,331,106) | 2.60 ± 0.04 | 2.44 ± 0.05 | 2.61 ± 0.05 | 2.92 ± 0.07 |
| Lower Limbs Erythema, Week 4 (n=320,323,328,102) | 2.17 ± 0.05 | 1.98 ± 0.05 | 2.15 ± 0.05 | 2.75 ± 0.07 |
| Lower Limbs Erythema, Week 8 (n=315,319,323,99) | 1.77 ± 0.06 | 1.50 ± 0.05 | 1.62 ± 0.05 | 2.55 ± 0.08 |
| Lower Limbs Erythema, Week 12 (n=313,311,309,95) | 1.56 ± 0.06 | 1.21 ± 0.06 | 1.35 ± 0.05 | 2.45 ± 0.09 |
| Lower Limbs Induration Baseline(n=329,329,335,107) | 2.94 ± 0.04 | 2.97 ± 0.04 | 3.00 ± 0.04 | 2.92 ± 0.07 |
| Lower Limbs Induration, Week 2 (n=326,326,331,106) | 2.47 ± 0.04 | 2.26 ± 0.05 | 2.45 ± 0.04 | 2.69 ± 0.07 |
| Lower Limbs Induration, Week 4 (n=320,323,328,102) | 2.03 ± 0.05 | 1.72 ± 0.05 | 1.92 ± 0.05 | 2.54 ± 0.07 |
| Lower Limbs Induration, Week 8 (n=315,319,323,99) | 1.58 ± 0.06 | 1.18 ± 0.05 | 1.38 ± 0.05 | 2.25 ± 0.08 |
| Lower Limbs Induration, Week 12 (n=313,311,309,95) | 1.40 ± 0.06 | 0.97 ± 0.05 | 1.10 ± 0.06 | 2.21 ± 0.08 |
| Lower Limbs Scaling, Baseline (n=329,329,335,107) | 2.91 ± 0.04 | 2.95 ± 0.04 | 2.98 ± 0.04 | 2.89 ± 0.07 |
| Lower Limbs Scaling, Week 2 (n=326,326,331,106) | 2.36 ± 0.05 | 2.25 ± 0.05 | 2.31 ± 0.05 | 2.62 ± 0.09 |
| Lower Limbs Scaling, Week 4 (n=320,323,328,102) | 1.98 ± 0.05 | 1.69 ± 0.06 | 1.81 ± 0.05 | 2.44 ± 0.09 |
| Lower Limbs Scaling, Week 8 (n=315,319,323,99) | 1.60 ± 0.06 | 1.21 ± 0.06 | 1.32 ± 0.05 | 2.11 ± 0.10 |
| Lower Limbs Scaling, Week 12 (n=313,311,309,95) | 1.39 ± 0.06 | 0.96 ± 0.06 | 1.08 ± 0.06 | 2.09 ± 0.10 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Head/Neck Erythema, Week 2 (n=326,326,331,106) | -0.46 ± 0.04 | -0.72 ± 0.05 | -0.56 ± 0.04 | -0.15 ± 0.06 |
| Head/Neck Erythema, Week 4 (n=320,323,328,102) | -0.80 ± 0.06 | -1.19 ± 0.06 | -1.10 ± 0.05 | -0.32 ± 0.07 |
| Head/Neck Erythema, Week 8 (n=315,319,323,99) | -1.09 ± 0.06 | -1.59 ± 0.06 | -1.63 ± 0.06 | -0.54 ± 0.10 |
| Head/Neck Erythema, Week 12 (n=313,311,309,95) | -1.25 ± 0.07 | -1.73 ± 0.07 | -1.83 ± 0.06 | -0.64 ± 0.12 |
| Head/Neck Induration, Week 2 (n=326,326,331,106) | -0.44 ± 0.04 | -0.65 ± 0.05 | -0.49 ± 0.04 | -0.17 ± 0.06 |
| Head/Neck Induration, Week 4 (n=320,323,328,102) | -0.83 ± 0.06 | -1.15 ± 0.06 | -0.95 ± 0.05 | -0.39 ± 0.08 |
| Head/Neck Induration, Week 8 (n=315,319,323,99) | -1.08 ± 0.06 | -1.50 ± 0.06 | -1.41 ± 0.06 | -0.58 ± 0.10 |
| Head/Neck Induration, Week 12 (n=313,311,309,95) | -1.19 ± 0.06 | -1.61 ± 0.06 | -1.57 ± 0.06 | -0.71 ± 0.11 |
| Head/Neck Scaling, Week 2 (n=326,326,331,106) | -0.53 ± 0.04 | -0.76 ± 0.05 | -0.67 ± 0.05 | -0.20 ± 0.07 |
| Head/Neck Scaling, Week 4 (n=320,323,328,102) | -0.91 ± 0.06 | -1.30 ± 0.07 | -1.13 ± 0.06 | -0.48 ± 0.08 |
| Head/Neck Scaling, Week 8 (n=315,319,323,99) | -1.16 ± 0.07 | -1.70 ± 0.06 | -1.62 ± 0.06 | -0.69 ± 0.10 |
| Head/Neck Scaling, Week 12 (n=313,311,309,95) | -1.31 ± 0.07 | -1.78 ± 0.07 | -1.81 ± 0.07 | -0.80 ± 0.11 |
| Upper Limbs Erythema, Week 2 (n=326,326,331,106) | -0.52 ± 0.04 | -0.68 ± 0.04 | -0.61 ± 0.04 | -0.18 ± 0.06 |
| Upper Limbs Erythema, Week 4 (n=320,323,328,102) | -0.94 ± 0.05 | -1.13 ± 0.05 | -1.11 ± 0.04 | -0.26 ± 0.07 |
| Upper Limbs Erythema, Week 8 (n=315,319,323,99) | -1.31 ± 0.06 | -1.60 ± 0.06 | -1.62 ± 0.05 | -0.49 ± 0.08 |
| Upper Limbs Erythema, Week 12 (n=313,311,309,95) | -1.42 ± 0.07 | -1.79 ± 0.06 | -1.95 ± 0.06 | -0.58 ± 0.09 |
| Upper Limbs Induration, Week 2 (n=326,326,331,106) | -0.52 ± 0.04 | -0.73 ± 0.04 | -0.59 ± 0.04 | -0.25 ± 0.05 |
| Upper Limbs Induration, Week 4 (n=320,323,328,102) | -0.94 ± 0.06 | -1.23 ± 0.05 | -1.13 ± 0.05 | -0.39 ± 0.07 |
| Upper Limbs Induration, Week 8 (n=315,319,323,99) | -1.26 ± 0.06 | -1.65 ± 0.06 | -1.54 ± 0.05 | -0.67 ± 0.08 |
| Upper Limbs Induration, Week 12 (n=313,311,309,95) | -1.39 ± 0.07 | -1.77 ± 0.06 | -1.92 ± 0.06 | -0.68 ± 0.10 |
| Upper Limbs Scaling, Week 2 (n=326,326,331,106) | -0.56 ± 0.04 | -0.72 ± 0.05 | -0.69 ± 0.04 | -0.28 ± 0.07 |
| Upper Limbs Scaling, Week 4 (n=320,323,328,102) | -0.96 ± 0.05 | -1.23 ± 0.06 | -1.19 ± 0.05 | -0.38 ± 0.08 |
| Upper Limbs Scaling, Week 8 (n=315,319,323,99) | -1.28 ± 0.06 | -1.62 ± 0.06 | -1.66 ± 0.06 | -0.64 ± 0.08 |
| Upper Limbs Scaling, Week 12 (n=313,311,309,95) | -1.36 ± 0.07 | -1.73 ± 0.06 | -1.92 ± 0.06 | -0.65 ± 0.10 |
| Trunk Erythema, Week 2 (n=326,326,331,106) | -0.54 ± 0.04 | -0.67 ± 0.04 | -0.63 ± 0.04 | -0.23 ± 0.06 |
| Trunk Erythema, Week 4 (n=320,323,328,102) | -0.91 ± 0.05 | -1.13 ± 0.05 | -1.16 ± 0.05 | -0.35 ± 0.06 |
| Trunk Erythema, Week 8 (n=315,319,323,99) | -1.23 ± 0.06 | -1.66 ± 0.06 | -1.67 ± 0.06 | -0.59 ± 0.08 |
| Trunk Erythema, Week 12 (n=313,311,309,95) | -1.41 ± 0.07 | -1.90 ± 0.07 | -2.03 ± 0.06 | -0.67 ± 0.10 |
| Trunk Induration, Week 2 (n=326,326,331,106) | -0.49 ± 0.04 | -0.69 ± 0.04 | -0.61 ± 0.04 | -0.27 ± 0.06 |
| Trunk Induration, Week 4 (n=320,323,328,102) | -0.93 ± 0.06 | -1.20 ± 0.06 | -1.17 ± 0.05 | -0.37 ± 0.07 |
| Trunk Induration, Week 8 (n=315,319,323,99) | -1.26 ± 0.06 | -1.74 ± 0.06 | -1.68 ± 0.06 | -0.62 ± 0.10 |
| Trunk Induration, Week 12 (n=313,311,309,95) | -1.43 ± 0.07 | -1.91 ± 0.07 | -1.99 ± 0.06 | -0.64 ± 0.11 |
| Trunk Scaling, Week 2 (n=326,326,331,106) | -0.52 ± 0.05 | -0.74 ± 0.05 | -0.64 ± 0.05 | -0.25 ± 0.07 |
| Trunk Scaling, Week 4 (n=320,323,328,102) | -0.92 ± 0.06 | -1.27 ± 0.06 | -1.15 ± 0.05 | -0.47 ± 0.08 |
| Trunk Scaling, Week 8 (n=315,319,323,99) | -1.19 ± 0.06 | -1.71 ± 0.06 | -1.67 ± 0.06 | -0.75 ± 0.09 |
| Trunk Scaling, Week 12 (n=313,311,309,95) | -1.38 ± 0.07 | -1.92 ± 0.06 | -1.94 ± 0.06 | -0.71 ± 0.10 |
| Lower Limbs Erythema, Week 2 (n=326,326,331,106) | -0.52 ± 0.04 | -0.69 ± 0.04 | -0.53 ± 0.04 | -0.20 ± 0.05 |
| Lower Limbs Erythema, Week 4 (n=320,323,328,102) | -0.95 ± 0.05 | -1.15 ± 0.05 | -1.00 ± 0.04 | -0.32 ± 0.06 |
| Lower Limbs Erythema, Week 8 (n=315,319,323,99) | -1.34 ± 0.06 | -1.63 ± 0.05 | -1.51 ± 0.05 | -0.55 ± 0.08 |
| Lower Limbs Erythema, Week 12 (n=313,311,309,95) | -1.55 ± 0.07 | -1.92 ± 0.07 | -1.80 ± 0.06 | -0.61 ± 0.09 |
| Lower Limbs Induration, Week 2 (n=326,326,331,106) | -0.47 ± 0.04 | -0.71 ± 0.04 | -0.56 ± 0.04 | -0.24 ± 0.05 |
| Lower Limbs Induration, Week 4 (n=320,323,328,102) | -0.92 ± 0.05 | -1.25 ± 0.05 | -1.08 ± 0.05 | -0.35 ± 0.07 |
| Lower Limbs Induration, Week 8 (n=315,319,323,99) | -1.37 ± 0.06 | -1.80 ± 0.06 | -1.62 ± 0.06 | -0.66 ± 0.08 |
| Lower Limbs Induration, Week 12 (n=313,311,309,95) | -1.56 ± 0.07 | -2.01 ± 0.06 | -1.91 ± 0.06 | -0.67 ± 0.09 |
| Lower Limbs Scaling, Week 2 (n=326,326,331,106) | -0.55 ± 0.04 | -0.69 ± 0.05 | -0.67 ± 0.04 | -0.27 ± 0.06 |
| Lower Limbs Scaling, Week 4 (n=320,323,328,102) | -0.94 ± 0.05 | -1.26 ± 0.06 | -1.18 ± 0.05 | -0.43 ± 0.09 |
| Lower Limbs Scaling, Week 8 (n=315,319,323,99) | -1.31 ± 0.06 | -1.74 ± 0.06 | -1.67 ± 0.06 | -0.75 ± 0.09 |
| Lower Limbs Scaling, Week 12 (n=313,311,309,95) | -1.53 ± 0.07 | -1.99 ± 0.06 | -1.92 ± 0.07 | -0.76 ± 0.10 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The % surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=329,329,335,107) | 32.15 ± 0.98 | 31.74 ± 0.95 | 30.63 ± 1.00 | 31.88 ± 1.62 |
| Week 2 (n=326,326,331,106) | 29.53 ± 0.96 | 28.12 ± 0.94 | 28.29 ± 0.97 | 32.03 ± 1.76 |
| Week 4 (n=320,323,328,102) | 25.98 ± 0.96 | 22.88 ± 0.93 | 24.82 ± 0.95 | 32.47 ± 1.89 |
| Week 8 (n=315,319,323,99) | 19.74 ± 0.98 | 14.76 ± 0.89 | 15.42 ± 0.81 | 31.00 ± 1.98 |
| Week 12 (n=313,311,309,95) | 16.04 ± 0.94 | 10.55 ± 0.77 | 10.60 ± 0.76 | 29.77 ± 2.12 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant(fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent change from baseline | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,326,331,106) | -7.54 ± 1.23 | -11.71 ± 1.12 | -7.54 ± 0.96 | 0.23 ± 1.89 |
| Week 4 (n=320,323,328,102) | -19.90 ± 1.66 | -29.17 ± 1.69 | -19.60 ± 1.46 | 1.58 ± 2.84 |
| Week 8 (n=315,319,323,99) | -37.81 ± 2.81 | -55.02 ± 1.93 | -48.65 ± 1.91 | -1.33 ± 3.57 |
| Week 12 (n=313,311,309,95) | -47.66 ± 3.35 | -67.51 ± 1.86 | -64.91 ± 1.91 | -6.68 ± 4.06 |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.
| percentage of participatns | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,327,331,106) | 10.74 | 18.35 | 11.18 | 0.94 |
| Week 4 (n=319,323,328,102) | 33.23 | 50.46 | 48.78 | 6.86 |
| Week 8 (n=315,319, 323,99) | 59.05 | 78.06 | 77.09 | 20.20 |
| Week 12 (n=313,311,309,95) | 69.01 | 85.53 | 87.06 | 23.16 |
| weeks | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Median Time to PASI50 Response During the 12-Week Double-Blind Treatment | 8.1 (NA to NA) | 5.0 (4.1 to 8.0) | 7.9 (4.4 to 8.0) | NA (NA to NA) |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0; higher scores represent greater severity of psoriasis.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,327,331,106) | 0.00 | 0.61 | 0.30 | 0.00 |
| Week 4 (n=319,323,328,102) | 1.57 | 4.64 | 1.83 | 0.00 |
| Week 8 (n=315,319,323,99) | 12.06 | 26.02 | 15.79 | 0.00 |
| Week 12 (n=313,311,309,95) | 22.04 | 38.26 | 34.95 | 1.05 |
| weeks | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Median Time to Achieve PASI75 Response During the 12-Week Double-Blind Treatment | 12.6 (12.4 to 13.1) | 8.6 (8.1 to 12.1) | 12.1 (11.1 to 12.1) | NA (NA to NA) |
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=326,327,331,106) | 0.92 | 0.61 | 0.30 | 4.72 |
| Week 4 (n=319,323,328,102) | 2.19 | 0.93 | 0.91 | 8.82 |
| Week 8 (n=315,319,323,99) | 2.54 | 0.31 | 0.31 | 7.07 |
| Week 12 (n=313,311,309,95) | 2.88 | 0.32 | 0.97 | 7.37 |
| Overall (n=327,329,334,107) | 4.59 | 1.82 | 1.80 | 15.89 |
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=305,308,305,107) | 5.19 ± 0.16 | 5.26 ± 0.16 | 5.23 ± 0.15 | 5.15 ± 0.27 |
| Week 2 (n=325,322,330,105) | 3.47 ± 0.15 | 2.87 ± 0.14 | 3.90 ± 0.15 | 4.90 ± 0.30 |
| Week 4 (n=318,323,328,101) | 2.92 ± 0.15 | 1.86 ± 0.13 | 2.97 ± 0.13 | 4.65 ± 0.31 |
| Week 8 (n=313,315,320,100) | 2.11 ± 0.14 | 1.22 ± 0.11 | 2.06 ± 0.13 | 4.74 ± 0.32 |
| Week 12 (n=312,309,311,95) | 1.98 ± 0.14 | 1.25 ± 0.12 | 1.72 ± 0.13 | 4.75 ± 0.32 |
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 | -1.73 ± 0.15 | -2.39 ± 0.14 | -1.22 ± 0.15 | -0.26 ± 0.22 |
| Week 4 | -2.24 ± 0.18 | -3.43 ± 0.17 | -2.20 ± 0.15 | -0.44 ± 0.24 |
| Week 8 | -3.01 ± 0.18 | -4.02 ± 0.17 | -3.13 ± 0.17 | -0.46 ± 0.26 |
| Week 12 | -3.18 ± 0.18 | -3.96 ± 0.18 | -3.46 ± 0.19 | -0.43 ± 0.28 |
ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 | 10.42 | 13.88 | 10.54 | 1.02 |
| Week 4 | 15.66 | 34.28 | 14.09 | 2.13 |
| Week 8 | 29.45 | 47.83 | 28.67 | 6.38 |
| Week 12 | 31.64 | 51.85 | 40.07 | 6.74 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=328,326,332,106) | 12.98 ± 0.39 | 13.32 ± 0.38 | 12.73 ± 0.38 | 12.27 ± 0.69 |
| Week 4 (n=318,323,325,100) | 7.82 ± 0.36 | 5.95 ± 0.32 | 6.90 ± 0.35 | 10.51 ± 0.77 |
| Week 12 (n=306,305,307,93) | 5.61 ± 0.36 | 3.47 ± 0.27 | 3.84 ± 0.30 | 10.33 ± 0.81 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 4 (n=317,319,322,99) | -5.28 ± 0.35 | -7.43 ± 0.36 | -5.80 ± 0.33 | -1.64 ± 0.55 |
| Week 12 (n=305,301,305,93) | -7.33 ± 0.43 | -9.72 ± 0.40 | -8.97 ± 0.40 | -1.85 ± 0.66 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Symptoms and Feelings,Baseline (n=328,327,332,106) | 3.44 ± 0.09 | 3.49 ± 0.08 | 3.47 ± 0.08 | 3.46 ± 0.16 |
| Symptoms and Feelings, Week 4 (n=318,323,324,100) | 2.11 ± 0.08 | 1.63 ± 0.07 | 1.94 ± 0.07 | 2.92 ± 0.15 |
| Symptoms and Feelings, Week 12 (n=306,304,307,93) | 1.60 ± 0.09 | 1.04 ± 0.07 | 1.16 ± 0.07 | 2.85 ± 0.17 |
| Daily Activities,Baseline (n=327,327,332,106) | 2.76 ± 0.10 | 2.85 ± 0.09 | 2.76 ± 0.09 | 2.52 ± 0.16 |
| Daily Activities, Week 4 (n=318,322,324,100) | 1.68 ± 0.08 | 1.30 ± 0.08 | 1.53 ± 0.08 | 2.28 ± 0.18 |
| Daily Activities, Week 12 (n=306,305,306,93) | 1.19 ± 0.08 | 0.70 ± 0.07 | 0.79 ± 0.07 | 2.17 ± 0.19 |
| Leisure, Baseline (n=326,326,330,106) | 2.52 ± 0.11 | 2.67 ± 0.11 | 2.57 ± 0.11 | 2.25 ± 0.17 |
| Leisure, Week 4 (n=318,322,325,100) | 1.50 ± 0.09 | 1.14 ± 0.08 | 1.33 ± 0.09 | 1.84 ± 0.18 |
| Leisure, Week 12 (n=306,305,307,93) | 1.09 ± 0.09 | 0.70 ± 0.07 | 0.71 ± 0.07 | 1.90 ± 0.19 |
| Work and School,Baseline (n=328,327,331,106) | 1.12 ± 0.06 | 1.08 ± 0.06 | 1.06 ± 0.06 | 0.97 ± 0.11 |
| Work and School, Week 4 (n=318,323,325,100) | 0.56 ± 0.05 | 0.46 ± 0.05 | 0.54 ± 0.05 | 0.81 ± 0.11 |
| Work and School, Week 12 (n=306,304,307,92) | 0.41 ± 0.04 | 0.24 ± 0.04 | 0.32 ± 0.04 | 0.83 ± 0.12 |
| Personal Relationships,Baseline(n=328,326,332,106) | 1.95 ± 0.11 | 1.98 ± 0.10 | 1.67 ± 0.10 | 1.89 ± 0.18 |
| Personal Relationships, Week 4 (n=318,323,325,100) | 1.21 ± 0.09 | 0.90 ± 0.08 | 0.93 ± 0.08 | 1.64 ± 0.20 |
| Personal Relationships, Week 12 (n=306,305,307,93) | 0.85 ± 0.09 | 0.48 ± 0.06 | 0.52 ± 0.07 | 1.65 ± 0.20 |
| Treatment, Baseline(n=328,327,332,106) | 1.22 ± 0.06 | 1.24 ± 0.06 | 1.23 ± 0.06 | 1.18 ± 0.10 |
| Treatment, Week 4 (n=318,323,325,100) | 0.76 ± 0.05 | 0.52 ± 0.04 | 0.65 ± 0.04 | 1.02 ± 0.11 |
| Treatment, Week 12 (n=306,305,307,93) | 0.45 ± 0.04 | 0.31 ± 0.03 | 0.33 ± 0.04 | 0.95 ± 0.11 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Symptoms and Feelings, Week 4 (n=317,320,321,99) | -1.34 ± 0.09 | -1.87 ± 0.08 | -1.53 ± 0.08 | -0.53 ± 0.15 |
| Symptoms and Feelings, Week 12 (n=305,301,305,93) | -1.81 ± 0.10 | -2.41 ± 0.10 | -2.30 ± 0.10 | -0.62 ± 0.18 |
| Daily Activities, Week 4 (n=316,319,321,99) | -1.13 ± 0.09 | -1.57 ± 0.09 | -1.21 ± 0.09 | -0.28 ± 0.15 |
| Daily Activities, Week 12 (n=304,302,304,93) | -1.58 ± 0.10 | -2.14 ± 0.10 | -1.96 ± 0.10 | -0.34 ± 0.19 |
| Leisure, Week 4 (n=316,318,320,99) | -1.03 ± 0.10 | -1.54 ± 0.10 | -1.24 ± 0.10 | -0.39 ± 0.15 |
| Leisure, Week 12 (n=303,301,303,93) | -1.41 ± 0.11 | -1.95 ± 0.11 | -1.90 ± 0.11 | -0.31 ± 0.18 |
| Work and School, Week 4 (n=317,320,321,99) | -0.56 ± 0.06 | -0.63 ± 0.06 | -0.52 ± 0.06 | -0.13 ± 0.10 |
| Work and School, Week 12 (n=305,301,304,92) | -0.69 ± 0.07 | -0.86 ± 0.06 | -0.77 ± 0.07 | -0.12 ± 0.10 |
| Personal Relationships, Week 4 (n=317,319,322,99) | -0.76 ± 0.09 | -1.09 ± 0.09 | -0.73 ± 0.08 | -0.18 ± 0.14 |
| Personal Relationships, Week 12 (n=305,301,305,93) | -1.10 ± 0.11 | -1.46 ± 0.10 | -1.17 ± 0.09 | -0.20 ± 0.15 |
| Treatment, Week 4 (n=317,320,322,99) | -0.47 ± 0.06 | -0.72 ± 0.06 | -0.58 ± 0.06 | -0.12 ± 0.10 |
| Treatment, Week 12 (n=305,302,305,93) | -0.75 ± 0.06 | -0.91 ± 0.06 | -0.91 ± 0.06 | -0.24 ± 0.10 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 4 | 60.93 | 71.38 | 61.35 | 36.59 |
| Week 12 | 71.54 | 85.28 | 81.34 | 35.90 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 4 | 13.07 | 21.79 | 15.51 | 7.37 |
| Week 12 | 33.22 | 51.36 | 47.18 | 8.89 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. DLQI Response was defined as a 5-point reduction in the total DLQI score.
No measurements were reported for this outcome.
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline Physical Health Score (n=327,327,327,105) | 47.4 ± 0.5 | 48.3 ± 0.5 | 47.5 ± 0.5 | 46.8 ± 1.0 |
| Week 12 Physical Health Score (n=303,304,307,95) | 51.7 ± 0.5 | 53.6 ± 0.4 | 52.5 ± 0.5 | 47.8 ± 1.0 |
| Baseline Mental Health Score (n=327,327,327,105) | 42.0 ± 0.6 | 41.2 ± 0.6 | 42.0 ± 0.7 | 39.8 ± 1.2 |
| Week 12 Mental Health Score (n=303,304,307,95) | 47.0 ± 0.6 | 49.3 ± 0.5 | 47.8 ± 0.6 | 41.7 ± 1.3 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline Physical Functioning (n=328,328,330,106) | 48.3 ± 0.5 | 49.0 ± 0.5 | 48.6 ± 0.5 | 46.7 ± 1.1 |
| Week 12 Physical Functioning (n=306,305,308,95) | 51.9 ± 0.5 | 53.1 ± 0.4 | 52.2 ± 0.4 | 48.1 ± 1.1 |
| Baseline Role Physical (n=328,328,330,106) | 45.4 ± 0.6 | 45.9 ± 0.6 | 45.5 ± 0.6 | 44.4 ± 1.1 |
| Week 12 Role Physical (n=307,305,308,95) | 50.5 ± 0.5 | 52.5 ± 0.4 | 51.2 ± 0.5 | 46.1 ± 1.1 |
| Baseline Bodily Pain (n=328,329,331,107) | 44.5 ± 0.7 | 45.6 ± 0.7 | 44.0 ± 0.7 | 43.6 ± 1.2 |
| Week 12 Bodily Pain (n=306,305,307,95) | 51.7 ± 0.6 | 54.6 ± 0.5 | 52.4 ± 0.6 | 45.7 ± 1.3 |
| Baseline General Health (n=328,328,330,106) | 43.4 ± 0.5 | 42.8 ± 0.5 | 43.5 ± 0.6 | 42.4 ± 1.0 |
| Week 12 General Health (n=305,304,308,95) | 46.2 ± 0.5 | 48.5 ± 0.5 | 47.9 ± 0.5 | 42.6 ± 1.0 |
| Baseline Vitality (n=328,329,331,107) | 47.9 ± 0.5 | 48.5 ± 0.6 | 48.3 ± 0.5 | 46.5 ± 1.0 |
| Week 12 Vitality (n=306,305,307,95) | 52.4 ± 0.5 | 54.4 ± 0.5 | 52.9 ± 0.5 | 47.9 ± 1.1 |
| Baseline Social Functioning (n=328,329,331,107) | 41.6 ± 0.6 | 41.1 ± 0.6 | 42.3 ± 0.7 | 40.7 ± 1.2 |
| Week 12 Social Functioning (n=306,305,307,95) | 47.8 ± 0.6 | 50.6 ± 0.5 | 49.3 ± 0.5 | 42.0 ± 1.2 |
| Baseline Role-Emotional (n=328,329,331,107) | 43.2 ± 0.7 | 42.4 ± 0.7 | 43.1 ± 0.7 | 40.4 ± 1.3 |
| Week 12 Role-Emotional (n=306,305,307,95) | 48.6 ± 0.5 | 50.2 ± 0.5 | 48.6 ± 0.6 | 43.3 ± 1.4 |
| Baseline Mental Health (n=328,329,331,107) | 42.0 ± 0.6 | 41.5 ± 0.6 | 41.7 ± 0.7 | 39.5 ± 1.2 |
| Week 12 Mental Health (n=306,305,307,95) | 46.6 ± 0.6 | 48.9 ± 0.5 | 47.5 ± 0.6 | 41.4 ± 1.2 |
| Baseline Health Transition (n=328,329,331,107) | 3.2 ± 0.0 | 3.2 ± 0.0 | 3.1 ± 0.0 | 3.2 ± 0.1 |
| Week 12 Health Transition (n=306,305,307,95) | 2.6 ± 0.0 | 2.6 ± 0.0 | 2.5 ± 0.0 | 3.0 ± 0.1 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Physical Health Score | 4.1 ± 0.4 | 5.0 ± 0.5 | 5.2 ± 0.5 | 0.8 ± 0.7 |
| Mental Health Score | 5.0 ± 0.6 | 7.6 ± 0.6 | 5.8 ± 0.6 | 1.5 ± 1.1 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Physical Functioning | 3.5 ± 0.4 | 3.7 ± 0.4 | 3.7 ± 0.5 | 1.1 ± 0.8 |
| Role Physical | 5.1 ± 0.5 | 6.3 ± 0.6 | 6.1 ± 0.5 | 1.3 ± 0.9 |
| Bodily Pain | 7.0 ± 0.7 | 8.5 ± 0.6 | 8.6 ± 0.7 | 1.6 ± 1.0 |
| General Health | 2.5 ± 0.5 | 5.5 ± 0.5 | 4.4 ± 0.5 | 0.2 ± 0.8 |
| Vitality | 4.2 ± 0.5 | 5.4 ± 0.5 | 4.6 ± 0.5 | 1.3 ± 0.9 |
| Social Functioning | 6.0 ± 0.7 | 9.2 ± 0.6 | 7.3 ± 0.6 | 0.7 ± 1.1 |
| Role - Emotional | 5.4 ± 0.6 | 7.2 ± 0.6 | 5.8 ± 0.7 | 2.3 ± 1.2 |
| Mental Health | 4.5 ± 0.6 | 7.0 ± 0.6 | 5.9 ± 0.6 | 1.4 ± 1.1 |
| Health Transition | -0.5 ± 0.1 | -0.6 ± 0.1 | -0.6 ± 0.1 | -0.2 ± 0.1 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Clear, Baseline (n=328,328,330,107) | 0.0 | 0.0 | 0.0 | 0.0 |
| Almost Clear, Baseline (n=328,328,330,107) | 0.0 | 0.3 | 0.3 | 0.0 |
| Mild, Baseline (n=328,328,330,107) | 3.4 | 1.5 | 4.2 | 3.7 |
| Moderate, Baseline (n=328,328,330,107) | 32.3 | 30.2 | 28.5 | 23.4 |
| Severe, Baseline (n=328,328,330,107) | 64.3 | 68.0 | 67.0 | 72.9 |
| Clear, Week 2 (n=324,322,331,106) | 0.3 | 0.0 | 0.3 | 0.0 |
| Almost Clear, Week 2 (n=324,322,331,106) | 1.2 | 4.3 | 1.2 | 0.9 |
| Mild, Week 2 (n=324,322,331,106) | 13.3 | 14.9 | 11.8 | 2.8 |
| Moderate, Week 2 (n=324,322,331,106) | 49.4 | 54.3 | 52.0 | 38.7 |
| Severe, Week 2 (n=324,322,331,106) | 35.8 | 26.4 | 34.7 | 57.5 |
| Clear, Week 4 (n=319,323,324,100) | 0.3 | 0.6 | 0.3 | 0.0 |
| Almost Clear, Week 4 (n=319,323,324,100) | 6.9 | 17.0 | 9.3 | 0.0 |
| Mild, Week 4 (n=319,323,324,100) | 21.6 | 30.7 | 26.5 | 5.0 |
| Moderate, Week 4 (n=319,323,324,100) | 46.7 | 36.8 | 43.5 | 35.0 |
| Severe, Week 4 (n=319,323,324,100) | 24.5 | 14.9 | 20.4 | 60.0 |
| Clear, Week 8 (n=313,317,315,97) | 2.9 | 4.7 | 3.5 | 0.0 |
| Almost Clear, Week 8 (n=313,317,315,97) | 16.9 | 38.2 | 29.8 | 4.1 |
| Mild, Week 8 (n=313,317,315,97) | 33.5 | 27.1 | 33.0 | 7.2 |
| Moderate, Week 8 (n=313,317,315,97) | 31.3 | 22.1 | 24.8 | 38.1 |
| Severe, Week 8 (n=313,317,315,97) | 15.3 | 7.9 | 8.9 | 50.5 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe). Response defined as score of 0 or 1.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Week 2 (n=324,322,331,106) | 1.54 | 4.35 | 1.51 | 0.94 |
| Week 4 (n=319,323,324,100) | 7.21 | 17.65 | 9.57 | 0.00 |
| Week 8 (n=313,317,315,97) | 19.81 | 42.90 | 33.33 | 4.12 |
| Week 12 (n=306,304,309,95) | 32.68 | 56.25 | 53.07 | 1.05 |
The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Very satisfied | 44.0 | 68.5 | 62.4 | 15.8 |
| Somewhat satisfied | 27.0 | 17.4 | 23.5 | 15.8 |
| Slightly satisfied | 11.7 | 5.2 | 7.2 | 11.6 |
| Neither satisfied nor dissatisfied | 4.6 | 2.3 | 2.0 | 11.6 |
| Slightly dissatisfied | 2.6 | 1.6 | 2.0 | 4.2 |
| Somewhat dissatisfied | 4.6 | 3.0 | 2.0 | 12.6 |
| Very dissatisfied | 5.5 | 2.0 | 1.0 | 28.4 |
The PSSM is a single, 7 point item that evaluates overall participant satisfaction with the study treatment. Response options range from "very dissatisfied" to "very satisfied" with the study medication.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Percentage of Participants Achieving PSSM Response of 'Very Satisfied' or 'Somewhat Satisfied' at Week 12 | 71.01 | 85.90 | 85.95 | 31.58 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline | 0.7 ± 0.0 | 0.7 ± 0.0 | 0.7 ± 0.0 | 0.6 ± 0.0 |
| Week 12 | 0.8 ± 0.0 | 0.9 ± 0.0 | 0.9 ± 0.0 | 0.7 ± 0.0 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Least Squares (LS) Mean Change From Baseline in EQ-5D Health State Utility Score During the 12-Week Double-Blind Treatment | 0.14 ± 0.011 | 0.21 ± 0.011 | 0.19 ± 0.011 | 0.03 ± 0.021 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
| mm | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=315,318,312,100) | 63.3 ± 1.3 | 63.3 ± 1.3 | 64.2 ± 1.3 | 60.5 ± 2.7 |
| Week 12 (n=298,294,297,91) | 75.3 ± 1.1 | 81.1 ± 1.0 | 80.0 ± 1.0 | 65.1 ± 2.6 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.
| mm | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Mean Change From Baseline in EQ-5D VAS at Week 12 | 11.6 ± 1.4 | 16.6 ± 1.5 | 15.7 ± 1.4 | 3.0 ± 2.4 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
| Units on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Mobility, Baseline (n=326,327,330,104) | 1.3 ± 0.0 | 1.3 ± 0.0 | 1.3 ± 0.0 | 1.3 ± 0.0 |
| Mobility, Week 12 (n=306,304,307,95) | 1.2 ± 0.0 | 1.1 ± 0.0 | 1.2 ± 0.0 | 1.3 ± 0.1 |
| Self Care, Baseline (n=327,327,330,104) | 1.2 ± 0.0 | 1.1 ± 0.0 | 1.1 ± 0.0 | 1.2 ± 0.0 |
| Self Care, Week 12 (n=306,304,307,95) | 1.1 ± 0.0 | 1.0 ± 0.0 | 1.1 ± 0.0 | 1.2 ± 0.0 |
| Usual Activities, Baseline (n=327,327,330,104) | 1.4 ± 0.0 | 1.4 ± 0.0 | 1.4 ± 0.0 | 1.5 ± 0.1 |
| Usual Activities, Week 12 (n=307,304,307,95) | 1.2 ± 0.0 | 1.1 ± 0.0 | 1.2 ± 0.0 | 1.3 ± 0.1 |
| Pain/Discomfort, Baseline (n=327,328,330,104) | 1.8 ± 0.0 | 1.8 ± 0.0 | 1.9 ± 0.0 | 1.8 ± 0.1 |
| Pain/Discomfort, Week 12 (n=307,304,307,95) | 1.5 ± 0.0 | 1.3 ± 0.0 | 1.4 ± 0.0 | 1.7 ± 0.1 |
| Anxiety/Depression, Baseline (n=326,327,330,104) | 1.6 ± 0.0 | 1.7 ± 0.0 | 1.6 ± 0.0 | 1.7 ± 0.1 |
| Anxiety/Depression, Week 12 (n=305,304,307,95) | 1.4 ± 0.0 | 1.3 ± 0.0 | 1.3 ± 0.0 | 1.5 ± 0.1 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Mobility | -0.1 ± 0.0 | -0.1 ± 0.0 | -0.1 ± 0.0 | -0.0 ± 0.0 |
| Self-Care | -0.1 ± 0.0 | -0.1 ± 0.0 | -0.1 ± 0.0 | -0.1 ± 0.0 |
| Usual Activities | -0.3 ± 0.0 | -0.3 ± 0.0 | -0.2 ± 0.0 | -0.1 ± 0.1 |
| Pain/Discomfort | -0.4 ± 0.0 | -0.5 ± 0.0 | -0.5 ± 0.0 | -0.1 ± 0.1 |
| Anxiety/Depression | -0.2 ± 0.0 | -0.4 ± 0.0 | -0.3 ± 0.0 | -0.1 ± 0.1 |
The Psoriasis Health Care Resource Utilization (Ps-HCRU) questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The first section assesses direct costs associated with healthcare resource use (interactions with healthcare providers such as general practitioners \[GPs\], primary care physicians \[PCPs\], or family medicine physicians \[FMP\], emergency room visits, and hospitalizations), and the second section assesses indirect costs associated with absenteeism due to psoriasis and the impact of psoriasis on productivity at work.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline, GP/PCP/FMP (n=230,220,224,77) | 0.8 | 0.9 | 1.3 | 2.5 |
| Baseline, Dermatologist (n=230,220,224,77) | 6.9 | 4.5 | 7.5 | 10.3 |
| Baseline, Rheumatologist (n=230,220,224,77) | 0.0 | 0.0 | 0.0 | 0.0 |
| Baseline, Cardiologist (n=230,220,224,77) | 0.4 | 0.4 | 0.4 | 2.5 |
| Baseline, Gastroenterologist (n=230,220,224,77) | 0.4 | 0.0 | 0.0 | 0.0 |
| Baseline, Psychiatrist (n=230,220,224,77) | 0.0 | 0.4 | 0.0 | 1.2 |
| Baseline, Surgeon (n=230,220,224,77) | 0.4 | 0.0 | 0.0 | 0.0 |
| Baseline, Nurse (n=230,220,224,77) | 1.3 | 1.3 | 0.8 | 2.5 |
| Baseline, Other (n=230,220,224,77) | 2.1 | 0.9 | 0.0 | 1.2 |
| Week 12, GP/PCP/FMP (n=255,251,261,79) | 10.1 | 6.7 | 8.4 | 8.8 |
| Week 12, Dermatologist (n=255,251,261,79) | 8.2 | 4.3 | 5.7 | 7.5 |
| Week 12, Rheumatologist (n=255,251,261,79) | 0.7 | 1.1 | 0.7 | 0.0 |
| Week 12, Cardiologist (n=255,251,261,79) | 1.5 | 1.9 | 2.6 | 1.2 |
| Week 12, Gastroenterologist (n=255,251,261,79) | 1.1 | 1.5 | 1.5 | 0.0 |
| Week 12, Psychiatrist (n=255,251,261,79) | 0.0 | 0.7 | 1.5 | 0.0 |
| Week 12, Surgeon (n=255,251,261,79) | 0.3 | 0.3 | 0.0 | 0.0 |
| Week 12, Nurse (n=255,251,261,79) | 1.1 | 1.9 | 2.6 | 0.0 |
| Week 12, Other (n=255,251,261,79) | 8.6 | 5.1 | 6.8 | 2.5 |
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Percentage of Participants Reporting Healthcare Resource Use Events During the 12-Week Double-Blind Treatment | 10.43 | 9.78 | 10.08 | 8.45 |
Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. The questionnaire assesses employment status of participant (employed: yes or no) and if currently employed it asks the participant if they were absent or on sick leave from work due to psoriasis; if unemployed it asks the participant if the unemployment is due to psoriasis.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline, employed | 67.8 | 71.2 | 72.3 | 71.4 |
| Baseline, absent/sick leave due to psoriasis | 18.3 | 21.0 | 22.3 | 23.4 |
| Baseline, not employed | 32.2 | 28.8 | 27.7 | 28.6 |
| Baseline, unemployed due to psoriasis | 9.6 | 7.3 | 6.3 | 2.6 |
| Week 12, employed | 69.2 | 73.8 | 69.1 | 68.1 |
| Week 12, absent/sick leave due to psoriasis | 13.2 | 14.7 | 15.7 | 17.4 |
| Week 12, not employed | 30.8 | 26.2 | 30.9 | 31.9 |
| Week 12, unemployed due to psoriasis | 4.0 | 4.9 | 4.7 | 4.3 |
Psoriasis Health Care Resource Utilization Questionnaire is a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work.
| percentage of participants | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Percentage of Participants Reporting Work-Impacted Events During the 12-Week Double-Blind Treatment | 37.97 | 30.49 | 34.15 | 56.25 |
The PQOL-12 is a 12-item questionnaire; 8 of the items on the Koo-Menter Psoriasis Index 12-item Quality of Life Questionnaire (PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.
| score on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Baseline (n=323,326,331,105) | 75.4 ± 1.5 | 77.0 ± 1.5 | 75.7 ± 1.5 | 74.9 ± 2.9 |
| Week 12 (n=303,303,306,92) | 40.0 ± 1.8 | 29.2 ± 1.6 | 31.0 ± 1.7 | 65.5 ± 3.5 |
The PQOL-12 is a 12-item questionnaire; 8 of the items on the PQOL-12) focus on emotional issues associated with psoriasis (self conscious, helpless, embarrassed, ability to enjoy life). The last 4 items deal with physical symptoms (pain or soreness, itch, physical irritation) and choice of clothing. The recall period is over the past month. The questions are answered on a scale from 0 to 10 with 0 being best and 10 being worst. Scores from each question are summed to give a total score (range 0 -120); higher scores indicate greater impairment to quality of life.
| scores on a scale | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW |
|---|---|---|---|---|
| Mean Change From Baseline in PQOL-12 Score During the 12-Week Double-Blind Treatment | -35.2 ± 1.9 | -47.9 ± 1.8 | -44.3 ± 1.8 | -9.6 ± 2.6 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 5 mg BID | — | 7/329 (2.1%) | 103/329 (31.3%) |
| CP-690,550 10 mg BID | — | 5/330 (1.5%) | 121/330 (36.7%) |
| Etanercept 50 mg BIW | — | 7/335 (2.1%) | 109/335 (32.5%) |
| Placebo | — | 2/107 (1.9%) | 34/107 (31.8%) |
| Event | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Etanercept 50 mg BIW | Placebo |
|---|---|---|---|---|
| PsoriasisSkin and subcutaneous tissue disorders | 0/329 | 2/330 | 1/335 | 2/107 |
| Oedema peripheralGeneral disorders | 0/329 | 0/330 | 0/335 | 1/107 |
| Myocardial infarctionCardiac disorders | 1/329 | 0/330 | 0/335 | 0/107 |
| DiverticulitisInfections and infestations | 1/329 | 0/330 | 0/335 | 0/107 |
| Extradural abscessInfections and infestations | 1/329 | 0/330 | 0/335 | 0/107 |
| Foot fractureInjury, poisoning and procedural complications | 1/329 | 0/330 | 0/335 | 0/107 |
| Lower limb fractureInjury, poisoning and procedural complications | 1/329 | 0/330 | 0/335 | 0/107 |
| Rib fractureInjury, poisoning and procedural complications | 1/329 | 0/330 | 0/335 | 0/107 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 1/329 | 0/330 | 0/335 | 0/107 |
| DepressionPsychiatric disorders | 1/329 | 0/330 | 0/335 | 0/107 |
| Event | CP-690,550 5 mg BID | CP-690,550 10 mg BID | Etanercept 50 mg BIW | Placebo |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 21/329 | 30/330 | 25/335 | 10/107 |
| HeadacheNervous system disorders | 21/329 | 24/330 | 13/335 | 4/107 |
| Injection site erythemaGeneral disorders | 0/329 | 1/330 | 18/335 | 0/107 |
| Blood creatine phosphokinase increasedInvestigations | 15/329 | 16/330 | 10/335 | 0/107 |
| DyslipidaemiaMetabolism and nutrition disorders | 10/329 | 15/330 | 3/335 | 1/107 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 11/329 | 14/330 | 5/335 | 2/107 |
| PsoriasisSkin and subcutaneous tissue disorders | 3/329 | 1/330 | 2/335 | 4/107 |
| Injection site reactionGeneral disorders | 0/329 | 0/330 | 12/335 | 0/107 |
| Blood cholesterol increasedInvestigations | 9/329 | 11/330 | 7/335 | 0/107 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/329 | 10/330 | 4/335 | 1/107 |
Full Analysis Set (FAS): included all participants who were randomized to the study and received at least 1 dose of the randomized investigational drug (CP-690,550, etanercept, or placebo).
| Age, Continuous(years) | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW | Total |
|---|---|---|---|---|---|
| Mean | 44.4 ± 12.1 | 43.6 ± 12.6 | 43.3 ± 12.2 | 46.1 ± 13.4 | 44.0 ± 12.4 |
| Sex: Female, Male(Participants) | CP-690,550 5 mg Twice Daily (BID)+Placebo Twice Weekly (BIW) | CP-690,550 10 mg BID + Placebo BIW | Placebo BID + Etanercept 50 mg BIW | Placebo BID + Placebo BIW | Total |
|---|---|---|---|---|---|
| Female | 93 | 92 | 102 | 36 | 323 |
| Male | 236 | 238 | 233 | 71 | 778 |
Showing the first 100 of 122 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib